RevBits Completes Development for its Privileged Access Management Solution to be Fully Deployable in a True Air Gapped Environment
22.5.2023 16:15:00 EEST | Business Wire | Press release
RevBits announces that it has successfully completed the architectural development of its privileged access management solution for deployment in a true air gapped environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005003/en/
RevBits Privileged Access Management (RB/PAM) is an advanced access management solution that includes seven modules and extensive session logging that captures keystrokes and video. These unique access control capabilities and multi-module offerings reduce vendor relationship management efforts and increase access management safeguards.
RevBits PAM has two U.S. patents - a browser-based zero-knowledge encryption and authentication authority that extends to various hardware security solutions.
RevBits PAM modules:
Privileged Access Management - regulates access to critical resources, captures keystrokes, and video records all privileged sessions.
Privileged Session Management - provides keystroke and query logging for all sessions through the solution's Jump Server.
Password Management - extends authentication security with hardware security modules, USB tokens, smart cards, near-field communications, and RFID.
Service Account Management - scans and onboards service accounts and scheduled tasks for IIS web applications.
Key Management - allows users to easily generate and store encryption keys.
Certificate Management - reports all expired or soon-to-expire certificates and vulnerable implementations of SSL.
CI/CD Integration - the CI/CD module plugs into your current platform and unlocks the capabilities of secure secret management across the CI/CD lifecycle, allowing for easy management of CI/CD users, credentials, and assets.
Defining Air Gap:
Techopedia: "An air gap is a security measure that isolates a digital device component or private local area network ( LAN ) from other devices and networks, including the public internet. An air gap is also known as an air wall , and the strategy of using air gaps to protect critical data is also known as security by isolation .
Air gaps are used to protect critical computer systems and the data they store from malware, keyloggers , ransomware, and other types of unauthorized access. This strategy seeks to ensure the total isolation of a given system electromagnetically, electronically, and physically."
RevBits Privileged Access Management – our Air Gap capability:
Inside the air gap environment sit servers and assets critical to the organization. As important as it is to protect against malware and ransomware attacks, it is equally important to protect the data on those servers from malicious acts and theft in an air gap environment.
RevBits Privileged Access Management is fully featured in an air gapped environment allowing for complete server security and data protection. Server access is monitored through extensive session monitoring, including video recording and keystroke logging.
About RevBits
Established in 2018, RevBits is a comprehensive cybersecurity company dedicated to providing customers with superior protection and service. RevBits delivers protection against the most sophisticated cyber threats companies face by offering multiple advanced security capabilities that can be administered through a unified security platform. RevBits is headquartered in Mineola, NY, with offices in Princeton, NJ; Boston, MA; London, England; and Antwerp, Belgium. For more information please visit RevBits.
RevBit's complete solution suite offerings are RevBits Endpoint Security, RevBits Email Security, RevBits Privileged Access Management, RevBits Zero Trust Network, and RevBits Deception Technology. For customers running more than one RevBits solution, the administration is managed through RevBits Cyber Intelligence Platform, a unified, single-pane environment that curates, correlates, and alerts to threats while delivering intelligence for a quick administrative response. RevBits Cyber Intelligence Platform integrates with all common SIEMs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005003/en/
Contact information
Neal Hesterberg
Vice President of Business Development
RevBits
neal.hesterberg@revbits.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
